Award recordCONTRACT

CORE TRADING CO

PIID 36C77018P1350· VHA· NATIONAL CMOP OFFICE (36C770)· 6505 · DRUGS AND BIOLOGICALS· FY2018· $90,056 net obligations· UEI HSYJHAJULQ94· VA

Description

NEFAZODONE 100MG; NEFAZODONE 200MG; MAGNESIUM OXIDE 140MG; CHOLESTYRAMINE 4GM/5GM LIGHT ORAL POWDER; CLINDAMYCIN HCL 150MG; NIACIN 250MG

First action · last action
2018-06-13 · 2018-09-26
Transactions
2
First transaction's obligation
$88,569
Base + all options value (sum of deltas)
$90,056
Extent competed
COMPETED UNDER SAP
Other than full & open authority
—
Set-aside
SERVICE DISABLED VETERAN OWNED SMALL BUSINESS SET-ASIDE
Offers received
5
SDVOSB flag on record
Yes (self-representation)
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$90,056$0Base award · 2018-06-13 · this action $88,569 · running total $88,569Modification P00001 · 2018-09-26 · this action $1,487 · running total $90,056
  • Base2018-06-13+$88,569= $88,569
  • Mod P000012018-09-26+$1,487= $90,056
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2018-06-13+$88,569$88,569NEFAZODONE 100MG; NEFAZODONE 200MG; MAGNESIUM OXIDE 140MG; CHOLESTYRAMINE 4GM/5GM LIGHT ORAL POWDER; CLINDAMYC…
Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE2018-09-26+$1,487$90,056NEFAZODONE 100MG; NEFAZODONE 200MG; MAGNESIUM OXIDE 140MG; CHOLESTYRAMINE 4GM/5GM LIGHT ORAL POWDER; CLINDAMYC…

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI HSYJHAJULQ94)

AwardOffice · PSC / listingNet obligationsFY
36C77026P0066NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$822,505FY2026
36C77026P0062NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$64,656FY2026
36C77025P0236NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$54,060FY2025
36C77025P0133NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$113,280FY2025
36C77025P0100NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$557,700FY2025
36C77025P0099NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS$162,394FY2025

Other recipients under 6505 from NATIONAL CMOP OFFICE (36C770) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C77026P0118HYGEN PHARMACEUTICALS INCNATIONAL CMOP OFFICE (36C770)$30,935FY2026
36C77026P0129DERRAH MORRISON ENTERPRISES LLCNATIONAL CMOP OFFICE (36C770)$76,656FY2026
36C77026P0127DERRAH MORRISON ENTERPRISES LLCNATIONAL CMOP OFFICE (36C770)$58,395FY2026
36C77026P0086SAGENT PHARMACEUTICALS, INCNATIONAL CMOP OFFICE (36C770)$275,580FY2026
36C77026P0095HYGEN PHARMACEUTICALS INCNATIONAL CMOP OFFICE (36C770)$83,520FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C77018P1350_3600_-NONE-_-NONE- · retrieved 2026-09-26.